Cargando…

SARS-CoV-2 structural features may explain limited neutralizing-antibody responses

Neutralizing antibody responses of SARS-CoV-2-infected patients may be low and of short duration. We propose here that coronaviruses employ a structural strategy to avoid strong and enduring antibody responses. Other viruses induce optimal and long-lived neutralizing antibody responses, thanks to 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachmann, Martin F., Mohsen, Mona O., Zha, Lisha, Vogel, Monique, Speiser, Daniel E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782831/ https://www.ncbi.nlm.nih.gov/pubmed/33398006 http://dx.doi.org/10.1038/s41541-020-00264-6

Ejemplares similares

Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism
por: Bachmann, Martin F., et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Low‐affinity but high‐avidity interactions may offer an explanation for IgE‐mediated allergen cross‐reactivity
por: Chang, Xinyue, et al.
Publicado: (2021)

Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain
por: Chang, Xinyue, et al.
Publicado: (2021)

Antibodies, epicenter of SARS-CoV-2 immunology
por: Pecetta, Simone, et al.
Publicado: (2021)

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
por: Augusto, Gilles, et al.
Publicado: (2021)

Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
por: Vogel, Monique, et al.
Publicado: (2021)

SARS-CoV-2: can isolation be limited to those who are truly infectious?
por: Vink, Elen, et al.
Publicado: (2022)

Dissecting antibody-mediated protection against SARS-CoV-2
por: Zohar, Tomer, et al.
Publicado: (2020)

COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020)

SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA
por: Flower, Barnaby, et al.
Publicado: (2020)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern
por: Rothen, Dominik A., et al.
Publicado: (2022)

Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2
por: Aringer, Martin
Publicado: (2021)

WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
por: Zhu, Feng, et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced antibody levels: what lies beneath
por: Lassaunière, Ria, et al.
Publicado: (2022)

Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles
por: Chang, Xinyue, et al.
Publicado: (2022)

Limited antibody specificity compromises epitranscriptomic analyses
por: Helm, Mark, et al.
Publicado: (2019)

Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
por: Chang, Xinyue, et al.
Publicado: (2023)

B cells: more than just for antibodies in SARS-CoV-2 vaccine responses
por: Paley, Michael A, et al.
Publicado: (2021)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2
por: Strugnell, Richard, et al.
Publicado: (2021)

Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
por: Raiden, Silvina, et al.
Publicado: (2021)

TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization
por: Chang, Xinyue, et al.
Publicado: (2022)

Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
por: Zha, Lisha, et al.
Publicado: (2021)

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases
por: Goulenok, Tiphaine, et al.
Publicado: (2022)

Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis
por: Wallwork, Rachel, et al.
Publicado: (2022)

Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
por: Nadesalingam, Angalee, et al.
Publicado: (2021)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Shao, Yacong, et al.
Publicado: (2022)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

Asymptomatic SARS-CoV-2 infection
por: Ooi, Eng Eong, et al.
Publicado: (2020)

The complexities of SARS-CoV-2 serology
por: Houlihan, Catherine F, et al.
Publicado: (2020)

Neonatal SARS-CoV-2 infection
por: de Carvalho, Werther Brunow, et al.
Publicado: (2020)

Towards SARS-CoV-2 serotypes?
por: Simon-Loriere, Etienne, et al.
Publicado: (2022)

The development of neutralizing antibodies against SARS-CoV-2 and their common features
por: Liu, Liu Daisy, et al.
Publicado: (2020)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

Understanding the drivers of transmission of SARS-CoV-2
por: Cornelissen, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r9mt4levfiq6at4q8inrudaaoe